Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer

利用 RB1 缺陷治疗致命性神经内分泌前列腺癌

基本信息

  • 批准号:
    9763338
  • 负责人:
  • 金额:
    $ 49.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Metastatic prostate cancer is incurable with available therapies and accounts for all prostate cancer mortality. This is a significant health problem given that prostate cancer is the most common visceral cancer in men and the second leading cause of cancer death in western societies. Androgen deprivation therapy (ADT) is the most generally useful therapy available. Despite the initial effectiveness of this molecularly targeted therapy, however, patients will inevitably relapse with ADT resistant disease. Well characterized forms of ADT resistance include alterations in androgen receptor (AR) leading to persistent and sometimes ligand independent AR signaling as well as changes in steroid metabolism that maintain intratumoral androgen levels sufficient for AR signaling. Newer generation drugs like the superior AR antagonist enzalutamide or the CYP17A1 inhibitor abiraterone acetate counter these ADT resistance mechanisms and extend life in men with recurrent disease, but responses have proven short lived. Delaying or reversing ADT resistance, therefore, is an important therapeutic goal as it is proven to extend patient survival. As AR blockade has improved, a unique form of resistance involving trans differentiation to an AR negative cancer with neuroendocrine features (NEPC) is increasingly observed. NEPC progresses with atypical visceral metastasis in the absence of rising PSA, and is observed currently in about 25% of prostate cancer autopsies. Incidence is likely to increase as more patients benefit from improved ADT. Molecular mechanisms underlying NEPC trans differentiation are not clear, nor are there targeted therapies available to treat it. We present data from human cell lines and mouse models suggesting RB1 loss is a key determinant facilitating NEPC trans differentiation. We suggest Rb1 loss relieves a constraint on epigenetic reprogramming of gene expression thereby facilitating trans differentiation to AR negative, ADT resistant NEPC. If true, NEPC trans differentiation should be reversible. Consistent with this prediction, preliminary data indicates some epigenetic modulating drugs restore AR expression and enzalutamide sensitivity in NEPC. The specific goals of the proposed research are to challenge the central hypothesis, characterize mechanisms causing NEPC trans differentiation, assess their clinical relevance by cross-species analysis, and test their utility as therapeutic targets using pre-clinical trials. Successful completion of these goals will address a critical issue in the clinical management of prostate cancer and will fill major current gaps in our fundamental understanding of prostate cancer progression, therapeutic resistance, and the role that RB1 loss of function plays in these processes.
转移性前列腺癌用现有疗法无法治愈,并且导致所有前列腺癌死亡。 鉴于前列腺癌是男性和女性中最常见的内脏癌,这是一个重大的健康问题。 西方社会癌症死亡的第二大原因。雄激素剥夺疗法(ADT)是 最普遍有用的治疗方法。尽管这种分子靶向疗法最初有效, 然而,ADT 耐药性疾病患者将不可避免地复发。 ADT 的明确特征形式 耐药性包括雄激素受体 (AR) 的改变,导致持久性耐药,有时甚至是配体耐药 独立的 AR 信号传导以及维持瘤内雄激素水平的类固醇代谢变化 足够用于 AR 信号传输。新一代药物,如卓越的 AR 拮抗剂 enzalutamide 或 CYP17A1 抑制剂醋酸阿比特龙可对抗这些 ADT 耐药机制并延长男性患者的寿命 疾病反复发作,但事实证明反应是短暂的。因此,延迟或逆转 ADT 耐药性是 一个重要的治疗目标,因为它被证明可以延长患者的生存期。随着 AR 封锁的改进,一种独特的 涉及向具有神经内分泌特征的 AR 阴性癌症的转分化的耐药形式 (NEPC)越来越受到关注。 NEPC 在没有上升的情况下进展为非典型内脏转移 PSA,目前在约 25% 的前列腺癌尸检中观察到。发病率可能会增加 更多患者受益于 ADT 的改善。 NEPC 转分化的分子机制是 尚不清楚,也没有可用于治疗的靶向疗法。我们提供来自人类细胞系的数据 小鼠模型表明 RB1 丢失是促进 NEPC 反式分化的关键决定因素。我们建议 Rb1 缺失缓解了基因表达表观遗传重编程的限制,从而促进 反式分化为 AR 阴性、ADT 抗性 NEPC。如果属实,NEPC 反分化应该是 可逆。与这一预测一致,初步数据表明一些表观遗传调节药物可以恢复 NEPC 中的 AR 表达和恩杂鲁胺敏感性。拟议研究的具体目标是 挑战中心假设,描述引起 NEPC 转分化的机制,评估其 通过跨物种分析确定临床相关性,并使用临床前试验测试其作为治疗靶点的效用。 成功完成这些目标将解决前列腺癌临床管理中的一个关键问题 并将填补我们目前对前列腺癌进展、治疗的基本理解的主要空白 抵抗力,以及 RB1 功能丧失在这些过程中所起的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leigh Ellis其他文献

Leigh Ellis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leigh Ellis', 18)}}的其他基金

Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer
鉴定 RB 缺陷型前列腺癌中 EZH2 依赖性脆弱性
  • 批准号:
    10410374
  • 财政年份:
    2021
  • 资助金额:
    $ 49.06万
  • 项目类别:
Identifying EZH2-dependent vulnerabilities in RB deficient prostate cancer
鉴定 RB 缺陷型前列腺癌中 EZH2 依赖性脆弱性
  • 批准号:
    10154294
  • 财政年份:
    2021
  • 资助金额:
    $ 49.06万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient Prostate Cancer.
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点。
  • 批准号:
    10034539
  • 财政年份:
    2020
  • 资助金额:
    $ 49.06万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点
  • 批准号:
    10186723
  • 财政年份:
    2020
  • 资助金额:
    $ 49.06万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点
  • 批准号:
    10304098
  • 财政年份:
    2020
  • 资助金额:
    $ 49.06万
  • 项目类别:
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
ATR 依赖性作为致命性 RB 缺陷前列腺癌的新治疗靶点
  • 批准号:
    10472549
  • 财政年份:
    2020
  • 资助金额:
    $ 49.06万
  • 项目类别:
Novel Mouse Models to define Genetic Drivers of Aggressive Prostate Cancer
定义侵袭性前列腺癌遗传驱动因素的新型小鼠模型
  • 批准号:
    9461668
  • 财政年份:
    2016
  • 资助金额:
    $ 49.06万
  • 项目类别:
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
利用 RB1 缺陷治疗致命性神经内分泌前列腺癌
  • 批准号:
    9338195
  • 财政年份:
    2016
  • 资助金额:
    $ 49.06万
  • 项目类别:
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer
利用 RB1 缺陷治疗致命性神经内分泌前列腺癌
  • 批准号:
    9152986
  • 财政年份:
    2016
  • 资助金额:
    $ 49.06万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 49.06万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了